Ann Rheum Dis

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS REGISTER


[Advanced]
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this link to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Add article to my folders
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Sambrook, P N
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Sambrook, P N
Annals of the Rheumatic Diseases 2005;64:176-178
© 2005 by BMJ Publishing Group Ltd & European League Against Rheumatism

REVIEW

How to prevent steroid induced osteoporosis

P N Sambrook

Correspondence to:
Correspondence to:
Professor P N Sambrook
Royal North Shore Hospital, St Leonards, Sydney, Australia 2065; sambrook{at}med.usyd.ed.au


ABSTRACT
The first choice for prevention of corticosteroid osteoporosis is a potent oral bisphosphonate—for example, alendronate or risedronate. Intravenous bisphosphonates should be considered for patients intolerant of the oral route. For patients receiving chronic low dose corticosteroids treatment with calcium and vitamin D may prevent further bone loss. Use of parathyroid hormone is promising.

Abbreviations: BMD, bone mineral density; CS, corticosteroid(s); HT, hormone therapy; PTH, parathyroid hormone

Keywords: bisphosphonates; glucocorticoids; osteoporosis; vitamin D




This article has been cited by other articles:


Home page
 CirculationHome page
M. Imazio, A. Brucato, D. Cumetti, G. Brambilla, B. Demichelis, S. Ferro, S. Maestroni, E. Cecchi, R. Belli, G. Palmieri, et al.
Corticosteroids for Recurrent Pericarditis: High Versus Low Doses: A Nonrandomized Observation
Circulation, August 5, 2008; 118(6): 667 - 671.
[Abstract] [Full Text] [PDF]

Home page
 Ann Rheum DisHome page
M Guler-Yuksel, J Bijsterbosch, Y P M Goekoop-Ruiterman, J K de Vries-Bouwstra, H M J Hulsmans, W M de Beus, K H Han, F C Breedveld, B A C Dijkmans, C F Allaart, et al.
Changes in bone mineral density in patients with recent onset, active rheumatoid arthritis
Ann Rheum Dis, June 1, 2008; 67(6): 823 - 828.
[Abstract] [Full Text] [PDF]

Home page
 Ann Rheum DisHome page
C. Salvarani, N. Pipitone, L. Boiardi, and G. G Hunder
Do we need treatment with tumour necrosis factor blockers for giant cell arteritis?
Ann Rheum Dis, May 1, 2008; 67(5): 577 - 579.
[Full Text] [PDF]

Home page
 LupusHome page
A. Tincani, M. Nuzzo, A. Lojacono, M. Cattalini, and A. Meini
Review: Contraception in adolescents with systemic lupus erythematosus
Lupus, August 1, 2007; 16(8): 600 - 605.
[Abstract] [PDF]

Home page
 Rheumatology (Oxford)Home page
J. C. Buckland-Wright, E. A. Messent, C. O. Bingham III, R. J. Ward, and C. Tonkin
A 2 yr longitudinal radiographic study examining the effect of a bisphosphonate (risedronate) upon subchondral bone loss in osteoarthritic knee patients
Rheumatology, February 1, 2007; 46(2): 257 - 264.
[Abstract] [Full Text] [PDF]

Home page
 Am J Health Syst PharmHome page
A. Gaffo, K. G. Saag, and J. R. Curtis
Treatment of rheumatoid arthritis
Am. J. Health Syst. Pharm., December 15, 2006; 63(24): 2451 - 2465.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS REGISTER
Terms and conditions relating to subscriptions purchased online  ¦  Website terms and conditions  ¦  Privacy policy
Copyright © 2005 BMJ Publishing Group Ltd & European League Against Rheumatism